Doxacurium
As of the edition of 20 October 2026, Doxacurium is a small molecule: marketed, first approved in 1991 (US); acts on CHRNA1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1991
- Kind
- Small molecule
- Brand name
- Nuromax
- First approved
- 7 March 1991 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- AbbVie
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Doxacurium.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRNA1 | Acetylcholine receptor subunit alpha | P02708 |